Questcor Pharmaceuticals — Q1 2012 Earnings Presentation
12 slides from Questcor Pharmaceuticals's earnings presentation, Apr 26, 2012
Slide 1: First Quarter 2012 Conference Call
First Quarter 2012 Conference Call NASDAQ: QCOR Exhibit 99.3 First Quarter 2012 Conference Call NASDAQ: QCOR
Slide 2: Conference Call Logistics
2 • Today’s webcast, accompanying slide presentation and archived replay is available online at • Telephone replay is available by dialing: – U.S.: 855-859-2056 – International: 404-537-3406 – Replay Passcode: 70200329 Conference Call Logistics http://ir.questcor.com/events.cfm • Today’s webcast, ac
Slide 3: Safe Harbor Statement
3 Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performa
Slide 4: Strong First Quarter Results
4 • 238 paid NS scripts • 1,000 paid MS scripts – Up 97% YOY • 112 paid IS scripts • Record financial performance – 4,111 vials shipped, up 105% YOY – $96.0M in net sales, up 161% YOY – $0.58 GAAP EPS (diluted), up 241% YOY Strong First Quarter Results • 238 paid NS scripts • 1,000 paid MS scripts –
Slide 5: Paid Rxs NS Scripts - Strong Continued Growth
5 Paid Rxs NS Scripts-Strong Continued Growth Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is the fo
Slide 6: MS Scripts - Record of Consistent Growth
6 Notes: Historical trend information is not necessarily indicative of future results. Acthar is marketed for the on-label indication of MS exacerbations in adults, though the chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely rel
Slide 7: Monthly MS Scripts History
7 Monthly MS Scripts History Notes: Historical trend information is not necessarily indicative of future results. Acthar is marketed for the on-label indication of MS exacerbations in adults, though the chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the c
Slide 8: Shipped Vials
Shipped Vials Q1-10 Q2-40 Q3-10 Q410 Q1-41 Q2-44 Q3-114 Q441 Q1-12 =>Shipped Vials (® QUESTCOR
Slide 9: Understanding Acthar: the science of how it works
9 • Generating more data for on-label indications – NS – MS – IS – Lupus • Investigating Acthar in new indications – Diabetic nephropathy – Autism – Traumatic brain injury – ALS – Migraine Over 40 Acthar R&D and Investigator Initiated Research Studies Understanding Acthar: the science of how it work
Slide 10: Q1-2012 Financial Results
10 Q1 – 2012 Q1 – 2011 Q1-2012 Financial Results • First quarter vials shipped: 4,111 • First quarter cash flow from operations: $40.9M • Channel inventory estimated to be higher than fourth quarter • Medicaid reserves continue to appear adequate • 798,285 shares repurchased during Q1-2012 Record Ne
Slide 11: Questcor is Cash Flow Positive
11 04/20/12 Questcor is Cash Flow Positive *After return of $107 million of cash to shareholders through share repurchases. Debt-free balance sheet Cash / ST Investments $248M* Accounts Receivable $37M *After return of $107 million of cash to shareholders through share repurchases.
Slide 12: Investment Highlights
12 Investment Highlights 12 Acthar has sustainable competitive Acthar has sustainable competitive advantages-without FDA approval risk advantages-without FDA approval risk Acthar is approved for 19 indications-many Acthar is approved for 19 indications-many in large markets with sizable unmet need i
Questcor Pharmaceuticals — Q1 2012 Earnings Presentation on 6ix